Kymera Therapeutics, Inc. Common Stock KYMR
Analyst Ratings
- Consensus
- Buy — 21 Buy · 2 Hold · 0 Sell (23 analysts)
- Avg. Price Target
- $132.14 (+18.0% upside)
Key Stats
- Today's Range
- $111.42 – $116.20
- 50-Day Range
- $99.52 – $127.85
- 52-Week Range
- $39.84 – $130.05
- Volume
- 698K shs
- Average Volume
- 702K shs
- Market Cap
- $9.31 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 6.17
- Price / Sales
- 88.66
Short Interest
- Short Interest
- 0.24%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $105.00 million
- Net Income
- $-299,601,000
- Net Margin
- -285.34%
- Return on Equity
- -19.85%
- Debt-to-Equity
- —
About Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Related Stocks
Compare head-to-head: KYMR vs AMGN·KYMR vs MRNA·KYMR vs HALO·KYMR vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.